This study is looking at using the drug Canakinumab versus a placebo (non active treatment) as treatment for lung cancer patients whose tumor has been completely resected without any spread of or residual tumor. Patients are "randomized" on this study.  This means a computer tells the study team which treatment you will receive.  Neither the patient or the physician can choose the treatment assignment.  The purpose of Randomized trials is to equally study both treatment options using the same criteria in order to identify if one treatment may be superior to another treatment.